P. Hamann

发表

The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.

K. Myers, K. Marquette, N. Damle, 2008, International journal of oncology.

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples

I. Chaudhary, N. Damle, E. Boghaert, 2008, Cancer Chemotherapy and Pharmacology.

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

N. Damle, E. Boghaert, J. Dijoseph, 2007, Cancer Immunology, Immunotherapy.

Anticorps anti-5t4 humanises et conjugues anticorps anti-5t4/calicheamicine

K. Marquette, N. Damle, D. Gill, 2005 .

Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma

N. Damle, E. Boghaert, J. Dijoseph, 2004, Clinical Cancer Research.

The Efficient Synthesis of Two Prostaglandin Intermediates

A. Wissner, P. Hamann, 1989 .

Reactions of the trisulfide moiety in calicheamicin

M. Siegel, G. Ellestad, G. Morton, 1989 .

Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.

C. Discafani, S. Jones, N. Damle, 2006, International journal of oncology.

A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.

A. Mountain, C. Beyer, D. Shochat, 2005, Bioconjugate chemistry.

Monoclonal antibody–drug conjugates

P. Hamann, P. R. Hamann, 2005 .

An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.

I. Bernstein, C. Beyer, D. Flowers, 2002, Bioconjugate chemistry.

Synthesis and structure of the platelet aggregation factor thromboxane A2

W. C. Still, F. Fitzpatrick, S. Bunting, 1985, Nature.

Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates.

I. Hollander, A. Kunz, P. Hamann, 2008, Bioconjugate chemistry.

Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.

Ramaswamy Nilakantan, Frank Loganzo, Fei Ye, 2004, Bioorganic & medicinal chemistry letters.

Studies culminating in the total synthesis of (dl)-morphine

J. Toth, P. Fuchs, P. Hamann, 1988 .

Tandem intramolecular conjugate addition/intramolecular alkylation reactions of substituted vinyl sulfones

J. Toth, P. Fuchs, P. Hamann, 1984 .

Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content.

M. Karas, M. Siegel, B. Smith, 1991, Analytical chemistry.

Preparation of the 2,6-dioxa[3.1.1]Bicycloheptane nucleus of thromboxane A2

W. C. Still, P. Hamann, S. Bhagwat, 1985 .

Synthesis of Thromboxane A2

W. C. Still, S. Bhagwat, P. Hamann, 1985, Synfacts.

Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.

I. Wistuba, M. Follettie, C. Behrens, 2011, Cancer research.

Delineation of aCellular Hierarchy in LungCancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

I. Wistuba, M. Follettie, C. Behrens, 2011 .

Tumor and Stem Cell Biology Delineation of aCellular Hierarchy in LungCancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

I. Wistuba, M. Follettie, C. Behrens, 2011 .

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

N. Damle, E. Boghaert, J. Dijoseph, 2006, Clinical Cancer Research.

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

Irwin Hollander, I. Bernstein, H. Tsou, 2002, Bioconjugate chemistry.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Boris Gorovits, P. Frost, S. Stephens, 2004, Blood.

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22

A. Lawson, S. Stephens, N. Damle, 2004, Cancer Immunology, Immunotherapy.

Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

R. Wallace, F. Durr, P. Hamann, 1993, Cancer research.

Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts

P. Frost, N. Damle, E. Boghaert, 2004, Clinical Cancer Research.

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

I. Bernstein, I. Bernstein, J. Eary, 1996, Cancer research.

virus (RSV) vaccination model but does not adversely affect humoral responses in a respiratory syncytial B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model

Xiaochuan Zhou, M. Hegen, N. Damle, 2013 .

B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model.

Xiaochuan Zhou, M. Hegen, M. Collins, 2005, Blood.

Short title: Effect of B cell depletion in CIA and RSV models

Xiaochuan Zhou, M. Hegen, M. Collins, 2005 .

Antibody-Targeted Chemotherapy with Immunoconjugates of Calicheamicin: Differential Anti-Tumor Activity of Conjugated Calicheamicin Targeted to B-Cell Lymphoma Via B-Cell Lineage Specific Molecules CD19, CD20 and CD22.

N. Damle, E. Boghaert, J. Dijoseph, 2004 .

An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.

Ana T Menendez, L. Greenberger, F. Durr, 2005, Bioconjugate chemistry.

Determinants of the response of neuroblastoma cells to DNA damage: the roles of pre-treatment cell morphology and chemical nature of the damage.

P. Hamann, N. F. Schor, L. Hinman, 1996, The Journal of pharmacology and experimental therapeutics.